Stockreport

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases [Yahoo! Finan...

Organovo Holdings, Inc.  (ONVO) 
NASDAQ:AMEX Investor Relations: organovo.com/about/contact/investor-relations
PDF novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured i [Read more]